These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 36771465)

  • 1. Selected Aspects of the Intricate Background of Immune-Related Cholangiopathies-A Critical Overview.
    Kasztelan-Szczerbinska B; Rycyk-Bojarzynska A; Szczerbinska A; Cichoz-Lach H
    Nutrients; 2023 Feb; 15(3):. PubMed ID: 36771465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of cholestatic disease in 2017.
    de Vries E; Beuers U
    Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Aspects in the Management of Cholestatic Liver Diseases.
    Chazouillères O
    Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
    Poupon R
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel and emerging therapies for cholestatic liver diseases.
    Goldstein J; Levy C
    Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPAR-Mediated Bile Acid Glucuronidation: Therapeutic Targets for the Treatment of Cholestatic Liver Diseases.
    Gallucci GM; Hayes CM; Boyer JL; Barbier O; Assis DN; Ghonem NS
    Cells; 2024 Aug; 13(15):. PubMed ID: 39120326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gut-liver axis in cholangiopathies: focus on bile acid based pharmacological treatment.
    Cariello M; Gadaleta RM; Moschetta A
    Curr Opin Gastroenterol; 2022 Mar; 38(2):136-143. PubMed ID: 35034082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies.
    Trauner M; Halilbasic E; Kazemi-Shirazi L; Kienbacher C; Staufer K; Traussnigg S; Hofer H
    Dig Dis; 2014; 32(5):631-6. PubMed ID: 25034298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
    Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
    Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
    Kjærgaard K; Frisch K; Sørensen M; Munk OL; Hofmann AF; Horsager J; Schacht AC; Erickson M; Shapiro D; Keiding S
    J Hepatol; 2021 Jan; 74(1):58-65. PubMed ID: 32717289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrophages in cholangiopathies.
    Bruneau A; Guillot A; Tacke F
    Curr Opin Gastroenterol; 2022 Mar; 38(2):114-120. PubMed ID: 35098932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC).
    Mattner J
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow.
    Halilbasic E; Fuchs C; Hofer H; Paumgartner G; Trauner M
    Dig Dis; 2015; 33 Suppl 2():149-63. PubMed ID: 26641242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol.
    Ghonem NS; Auclair AM; Hemme CL; Gallucci GM; de la Rosa Rodriguez R; Boyer JL; Assis DN
    Clin Pharmacol Ther; 2020 Dec; 108(6):1213-1223. PubMed ID: 32480421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
    Rust C; Beuers U
    Clin Rev Allergy Immunol; 2005 Apr; 28(2):135-45. PubMed ID: 15879619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current Landscape and Evolving Therapies for Primary Biliary Cholangitis.
    Fiorucci S; Urbani G; Di Giorgio C; Biagioli M; Distrutti E
    Cells; 2024 Sep; 13(18):. PubMed ID: 39329760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bile Acids-Based Therapies for Primary Sclerosing Cholangitis: Current Landscape and Future Developments.
    Fiorucci S; Urbani G; Di Giorgio C; Biagioli M; Distrutti E
    Cells; 2024 Oct; 13(19):. PubMed ID: 39404413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Novel Insights of Primary Sclerosing Cholangitis and Primary Biliary Cholangitis].
    Ahn DW
    Korean J Gastroenterol; 2020 May; 75(5):246-256. PubMed ID: 32448856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis.
    Zein CO; Lindor KD
    Curr Gastroenterol Rep; 2010 Feb; 12(1):13-22. PubMed ID: 20425480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.